Head to Head Survey: Zimmer Biomet (NYSE:ZBH) and Artivion (NYSE:AORT)

Artivion (NYSE:AORT) and Zimmer Biomet (NYSE:ZBH) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their institutional ownership, earnings, profitability, analyst recommendations, dividends, valuation and risk.

Institutional & Insider Ownership

86.4% of Artivion shares are owned by institutional investors. Comparatively, 88.9% of Zimmer Biomet shares are owned by institutional investors. 6.3% of Artivion shares are owned by company insiders. Comparatively, 1.3% of Zimmer Biomet shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Artivion and Zimmer Biomet”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Artivion	$441.33 million	2.14	$9.77 million	($0.36)	-53.74
Zimmer Biomet	$8.23 billion	2.40	$705.20 million	$3.95	26.47

Zimmer Biomet has higher revenue and earnings than Artivion. Artivion is trading at a lower price-to-earnings ratio than Zimmer Biomet, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Artivion and Zimmer Biomet’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Artivion	-3.65%	5.12%	2.36%
Zimmer Biomet	8.95%	13.02%	7.17%

Analyst Recommendations

This is a summary of recent ratings for Artivion and Zimmer Biomet, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Artivion	1	0	6	0	2.71
Zimmer Biomet	1	16	7	0	2.25

Artivion presently has a consensus target price of $39.00, indicating a potential upside of 101.60%. Zimmer Biomet has a consensus target price of $112.74, indicating a potential upside of 7.82%. Given Artivion’s stronger consensus rating and higher possible upside, equities analysts plainly believe Artivion is more favorable than Zimmer Biomet.

Risk & Volatility

Artivion has a beta of 1.31, suggesting that its share price is 31% more volatile than the S&P 500. Comparatively, Zimmer Biomet has a beta of 0.5, suggesting that its share price is 50% less volatile than the S&P 500.

Summary

Zimmer Biomet beats Artivion on 9 of the 14 factors compared between the two stocks.

About Artivion

Artivion, Inc. is a medical device company focused on treating aortic disease and supporting cardiac and vascular surgery. Its products include aortic stent grafts and surgical grafts, mechanical heart valves, and BioGlue, a surgical adhesive used in cardiovascular procedures. The company was founded as CryoLife and adopted the Artivion name in 2022. It serves healthcare providers in the United States and international markets. Artivion is headquartered in Kennesaw, Georgia. Its chief executive officer is Pat Mackin.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc. develops and manufactures medical devices and technologies used in musculoskeletal care. Its products support orthopedic procedures involving the hip, knee, shoulder, and extremities, as well as trauma care, sports medicine, and related surgical applications. The company also offers surgical technologies, including robotic and digital solutions designed to assist clinicians with planning and performing procedures. Its products and services are used by hospitals, surgeons, and other healthcare providers.